Derek Thompson

what is the hope in terms of scaling up these kinds of therapies? Because I can imagine someone listening to this and thinking, this is incredibly exciting, but if we have to resect a tumor and then send the genetic material to Germany And then in a few days or weeks, Germany sends back to the doctor's office the recipe for the novel proteins that are being spit out by this virus, by this cancer.

what is the hope in terms of scaling up these kinds of therapies? Because I can imagine someone listening to this and thinking, this is incredibly exciting, but if we have to resect a tumor and then send the genetic material to Germany And then in a few days or weeks, Germany sends back to the doctor's office the recipe for the novel proteins that are being spit out by this virus, by this cancer.

what is the hope in terms of scaling up these kinds of therapies? Because I can imagine someone listening to this and thinking, this is incredibly exciting, but if we have to resect a tumor and then send the genetic material to Germany And then in a few days or weeks, Germany sends back to the doctor's office the recipe for the novel proteins that are being spit out by this virus, by this cancer.

And now you have to develop a vaccine to take on those novel proteins. It sounds like a very complicated process. It will be difficult to scale for a patient population that counts in the hundreds of millions. What is the hope on scaling?

And now you have to develop a vaccine to take on those novel proteins. It sounds like a very complicated process. It will be difficult to scale for a patient population that counts in the hundreds of millions. What is the hope on scaling?

And now you have to develop a vaccine to take on those novel proteins. It sounds like a very complicated process. It will be difficult to scale for a patient population that counts in the hundreds of millions. What is the hope on scaling?

Interesting. So it's sort of like, let's say that at a molecular level, we discover that there are basically, let's say, 30 types of pancreatic cancer. And you can just have those cancer vaccines all on a shelf. And I can have some genetic test that's done that gives my doctor a good sense that if I have this type of cancer, it's likely to be Pancreatic cancer type number 19.

Interesting. So it's sort of like, let's say that at a molecular level, we discover that there are basically, let's say, 30 types of pancreatic cancer. And you can just have those cancer vaccines all on a shelf. And I can have some genetic test that's done that gives my doctor a good sense that if I have this type of cancer, it's likely to be Pancreatic cancer type number 19.

Interesting. So it's sort of like, let's say that at a molecular level, we discover that there are basically, let's say, 30 types of pancreatic cancer. And you can just have those cancer vaccines all on a shelf. And I can have some genetic test that's done that gives my doctor a good sense that if I have this type of cancer, it's likely to be Pancreatic cancer type number 19.

And so you can dose me even before you've resected anything because you have a good enough idea that I'm likely to be a good candidate for that particular dose. rare disease vaccine.

And so you can dose me even before you've resected anything because you have a good enough idea that I'm likely to be a good candidate for that particular dose. rare disease vaccine.

And so you can dose me even before you've resected anything because you have a good enough idea that I'm likely to be a good candidate for that particular dose. rare disease vaccine.

Let's talk about some caveats here. First, to pick up on something you've said a few times, these vaccines are for secondary prevention. Can you spell that out?

Let's talk about some caveats here. First, to pick up on something you've said a few times, these vaccines are for secondary prevention. Can you spell that out?

Let's talk about some caveats here. First, to pick up on something you've said a few times, these vaccines are for secondary prevention. Can you spell that out?

The second caveat that I want us to hang with for a second is that you've alluded to the fact that this is not a randomized trial. This is a study that split patients into two groups, those who had a powerful immune response to the vaccine and those who didn't have a powerful response.

The second caveat that I want us to hang with for a second is that you've alluded to the fact that this is not a randomized trial. This is a study that split patients into two groups, those who had a powerful immune response to the vaccine and those who didn't have a powerful response.

The second caveat that I want us to hang with for a second is that you've alluded to the fact that this is not a randomized trial. This is a study that split patients into two groups, those who had a powerful immune response to the vaccine and those who didn't have a powerful response.

And the patients with the stronger immune response tended to stay cancer-free for longer, which suggests that something is working. But maybe that something is the vaccine, and maybe that something is not the vaccine. We don't know for sure without an RCT.

And the patients with the stronger immune response tended to stay cancer-free for longer, which suggests that something is working. But maybe that something is the vaccine, and maybe that something is not the vaccine. We don't know for sure without an RCT.